Vimta Labs Share Price
467.65+0.00 (-0.91%)
-23.52% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
KRT-RRNSE
SAGILITYNSE
PFOCUSNSE
IGILNSE
SYNGENENSE
INDGNNSE
HORIZONINDNSE
NESCONSE
SPARCNSE
SMARTWORKSNSE
VIMTALABSNSE
Vimta Labs Share Price
467.65+0.00 (-0.91%)
-23.52% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 13% | 14% | 9% | 18% |
| 28% | 30% | 18% | 16% |
| 26% | 21% | 30% | -24% |
| 14% | 19% | 18% | 19% |
Peer Comparison
Symbol
KRT-RR
SAGILITY
PFOCUS
IGIL
SYNGENE
INDGN
HORIZONIND
NESCO
SPARC
SMARTWORKS
VIMTALABS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 111.88 | ₹50313 Cr | — | — | — | ₹375 Cr |
| 44.4 | ₹20958 Cr | 20.42 | 0.61 | 3.28 | ₹925 Cr |
| 268 | ₹20813 Cr | 129.69 | 0.62 | 11.72 | ₹219 Cr |
| 432.9 | ₹18885 Cr | 28.37 | 4.3 | 16.67 | ₹711 Cr |
| 440 | ₹17665 Cr | 94.92 | 0.8 | 15.74 | ₹317 Cr |
| 656.45 | ₹15552 Cr | 37.83 | 4.67 | 24.19 | ₹401 Cr |
| 48.69 | ₹14097 Cr | — | 0.05 | 0.24 | -₹198 Cr |
| 1,065.55 | ₹7472 Cr | 18.55 | 14.93 | 64.11 | ₹413 Cr |
| 190.93 | ₹6252 Cr | 3.82 | -0.75 | 50.69 | ₹1553 Cr |
| 516.1 | ₹5895 Cr | 104.05 | 2.24 | 89.07 | ₹11 Cr |
| 467.7 | ₹2106 Cr | 26.21 | 4.61 | 28.96 | ₹78 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 | Mar 2015 | Dec 2014 | Sep 2014 | Jun 2014 | Mar 2014 | Dec 2013 | Sep 2013 | Jun 2013 | Mar 2013 | Dec 2012 | Sep 2012 | Jun 2012 | Mar 2012 | Dec 2011 | Sep 2011 | Jun 2011 | Mar 2011 | Dec 2010 | Sep 2010 | Jun 2010 | Mar 2010 | Dec 2009 | Sep 2009 | Jun 2009 | Mar 2009 | Dec 2008 | Sep 2008 | Jun 2008 | Mar 2008 | Dec 2007 | Sep 2007 | Jun 2007 | Mar 2007 | Dec 2006 | Sep 2006 | Jun 2006 | Mar 2006 | Dec 2005 | Sep 2005 | Jun 2005 | Mar 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹112 Cr | ₹109 Cr | ₹109 Cr | ₹99 Cr | ₹102 Cr | ₹98 Cr | ₹94 Cr | ₹90 Cr | ₹85 Cr | ₹75 Cr | ₹73 Cr | ₹73 Cr | ₹64 Cr | ₹82 Cr | ₹81 Cr | ₹76 Cr | ₹79 Cr | ₹79 Cr | ₹74 Cr | ₹67 Cr | ₹75 Cr | ₹61 Cr | ₹59 Cr | ₹58 Cr | ₹59 Cr | ₹33 Cr | ₹43 Cr | ₹51 Cr | ₹42 Cr | ₹44 Cr | ₹54 Cr | ₹51 Cr | ₹54 Cr | ₹55 Cr | ₹52 Cr | ₹47 Cr | ₹44 Cr | ₹39 Cr | ₹39 Cr | ₹39 Cr | ₹37 Cr | ₹37 Cr | ₹33 Cr | ₹30 Cr | ₹34 Cr | ₹28 Cr | ₹28 Cr | ₹25 Cr | ₹25 Cr | ₹29 Cr | ₹29 Cr | ₹31 Cr | ₹31 Cr | ₹27 Cr | ₹29 Cr | ₹27 Cr | ₹28 Cr | ₹26 Cr | ₹22 Cr | ₹20 Cr | ₹20 Cr | ₹25 Cr | ₹25 Cr | ₹26 Cr | ₹22 Cr | ₹23 Cr | ₹22 Cr | ₹20 Cr | ₹24 Cr | ₹22 Cr | ₹20 Cr | ₹16 Cr | ₹24 Cr | ₹21 Cr | ₹19 Cr | ₹21 Cr | ₹19 Cr | ₹18 Cr | ₹13 Cr | ₹15 Cr | ₹15 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹13 Cr | ₹13 Cr |
| ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹68 L | ₹69 L | ₹38 L | ₹70 L | ₹2 Cr | ₹59 L | ₹67 L | ₹1 Cr | ₹77 L | ₹90 L | ₹42 L | ₹72 L | ₹13 L | ₹18 L | ₹24 L | ₹30 L | ₹4 L | ₹23 L | ₹2 Cr | ₹84 L | ₹35 L | ₹15 L | ₹18 L | ₹2 L | ₹100 L | ₹73 L | ₹4 L | ₹37 L | ₹47 L | ₹33 L | ₹10 L | ₹53 L | ₹18 L | ₹45 L | ₹0 | ₹11 L | ₹84 L | ₹10 L | ₹40 L | ₹20 L | ₹6 L | ₹39 L | ₹1 Cr | ₹26 L | ₹1 Cr | ₹84 L | ₹52 L | ₹38 L | -₹27 L | ₹70 L | ₹2 Cr | ₹11 L | ₹46 L | ₹48 L | ₹6 L | ₹17 L | ₹6 L | ₹5 L | ₹71 L | ₹69 L | -₹3 L | ₹25 L | ₹3 L | ₹6 L | ₹2 L | ₹2 L | ₹48 L | ₹25 L | ₹61 L | ₹1 Cr | ₹57 L | ₹1 Cr | ₹2 Cr | ₹98 L | ₹23 L | ₹5 L | ₹20,000 | ₹8 L | ₹3 L |
| ₹115 Cr | ₹113 Cr | ₹112 Cr | ₹100 Cr | ₹105 Cr | ₹99 Cr | ₹96 Cr | ₹91 Cr | ₹85 Cr | ₹76 Cr | ₹73 Cr | ₹74 Cr | ₹66 Cr | ₹83 Cr | ₹81 Cr | ₹78 Cr | ₹80 Cr | ₹80 Cr | ₹74 Cr | ₹67 Cr | ₹75 Cr | ₹61 Cr | ₹60 Cr | ₹58 Cr | ₹59 Cr | ₹33 Cr | ₹45 Cr | ₹52 Cr | ₹43 Cr | ₹44 Cr | ₹54 Cr | ₹51 Cr | ₹55 Cr | ₹55 Cr | ₹52 Cr | ₹48 Cr | ₹44 Cr | ₹39 Cr | ₹40 Cr | ₹39 Cr | ₹37 Cr | ₹38 Cr | ₹33 Cr | ₹30 Cr | ₹35 Cr | ₹28 Cr | ₹29 Cr | ₹25 Cr | ₹25 Cr | ₹29 Cr | ₹31 Cr | ₹31 Cr | ₹32 Cr | ₹28 Cr | ₹29 Cr | ₹27 Cr | ₹27 Cr | ₹27 Cr | ₹25 Cr | ₹20 Cr | ₹21 Cr | ₹25 Cr | ₹25 Cr | ₹26 Cr | ₹23 Cr | ₹23 Cr | ₹22 Cr | ₹20 Cr | ₹24 Cr | ₹22 Cr | ₹20 Cr | ₹16 Cr | ₹24 Cr | ₹21 Cr | ₹20 Cr | ₹21 Cr | ₹20 Cr | ₹19 Cr | ₹13 Cr | ₹16 Cr | ₹17 Cr | ₹15 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹13 Cr | ₹13 Cr |
| ₹87 Cr | ₹84 Cr | ₹83 Cr | ₹75 Cr | ₹78 Cr | ₹74 Cr | ₹71 Cr | ₹67 Cr | ₹63 Cr | ₹57 Cr | ₹55 Cr | ₹58 Cr | ₹56 Cr | ₹67 Cr | ₹65 Cr | ₹63 Cr | ₹62 Cr | ₹62 Cr | ₹57 Cr | ₹52 Cr | ₹61 Cr | ₹50 Cr | ₹49 Cr | ₹47 Cr | ₹49 Cr | ₹35 Cr | ₹44 Cr | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹45 Cr | ₹42 Cr | ₹43 Cr | ₹45 Cr | ₹43 Cr | ₹38 Cr | ₹35 Cr | ₹36 Cr | ₹35 Cr | ₹34 Cr | ₹34 Cr | ₹33 Cr | ₹32 Cr | ₹27 Cr | ₹30 Cr | ₹26 Cr | ₹27 Cr | ₹24 Cr | ₹24 Cr | ₹26 Cr | ₹28 Cr | ₹26 Cr | ₹26 Cr | ₹23 Cr | ₹27 Cr | ₹25 Cr | ₹26 Cr | ₹25 Cr | ₹30 Cr | ₹23 Cr | ₹23 Cr | ₹26 Cr | ₹28 Cr | ₹25 Cr | ₹23 Cr | ₹22 Cr | ₹18 Cr | ₹22 Cr | ₹22 Cr | ₹19 Cr | ₹17 Cr | ₹17 Cr | ₹20 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹12 Cr | ₹13 Cr | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹7 Cr | ₹8 Cr |
| ₹41 Cr | ₹41 Cr | ₹42 Cr | ₹36 Cr | ₹37 Cr | ₹35 Cr | ₹35 Cr | ₹34 Cr | ₹31 Cr | ₹27 Cr | ₹26 Cr | ₹24 Cr | ₹19 Cr | ₹24 Cr | ₹24 Cr | ₹22 Cr | ₹26 Cr | ₹25 Cr | ₹23 Cr | ₹21 Cr | ₹20 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹16 Cr | ₹4 Cr | ₹7 Cr | ₹12 Cr | ₹7 Cr | ₹7 Cr | ₹14 Cr | ₹14 Cr | ₹17 Cr | ₹15 Cr | ₹14 Cr | ₹14 Cr | ₹12 Cr | ₹6 Cr | ₹7 Cr | ₹8 Cr | ₹6 Cr | ₹7 Cr | ₹4 Cr | ₹5 Cr | ₹7 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹8 Cr | ₹9 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | -₹1 Cr | ₹82 L | ₹1 Cr | ₹3 Cr | ₹1 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹7 Cr | ₹2 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹3 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹4 Cr | ₹7 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr |
| ₹39 L | ₹24 L | ₹32 L | ₹16 L | ₹37 L | ₹32 L | ₹44 L | ₹58 L | ₹41 L | ₹47 L | ₹53 L | ₹53 L | ₹61 L | ₹44 L | ₹25 L | ₹65 L | ₹80 L | ₹94 L | ₹57 L | ₹25 L | ₹24 L | ₹43 L | ₹68 L | ₹58 L | ₹32 L | ₹59 L | ₹1 Cr | ₹93 L | ₹99 L | ₹64 L | ₹43 L | ₹32 L | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹68 L | ₹51 L | ₹49 L | ₹41 L | ₹47 L | ₹34 L | ₹30 L | ₹20 L | ₹25 L | ₹21 L | ₹15 L | ₹11 L | ₹6 L | ₹42 L | ₹1 Cr | ₹85 L | ₹37 L | ₹53 L | ₹39 L | ₹1 Cr | ₹2 Cr | ₹77 L | ₹86 L | ₹51 L | ₹1 Cr | ₹72 L | ₹51 L | ₹43 L | ₹56 L | ₹80 L | ₹62 L | ₹64 L | ₹57 L | ₹75 L | ₹66 L | ₹64 L | ₹65 L | ₹74 L | ₹70 L | ₹72 L | ₹78 L | ₹1 Cr | ₹48 L | ₹25 L | ₹9 L | ₹12 L | ₹12 L | ₹9 L | ₹9 L |
| ₹28 Cr | ₹28 Cr | ₹29 Cr | ₹23 Cr | ₹26 Cr | ₹25 Cr | ₹25 Cr | ₹24 Cr | ₹22 Cr | ₹18 Cr | ₹18 Cr | ₹15 Cr | ₹10 Cr | ₹16 Cr | ₹16 Cr | ₹14 Cr | ₹18 Cr | ₹17 Cr | ₹16 Cr | ₹15 Cr | ₹13 Cr | ₹11 Cr | ₹10 Cr | ₹11 Cr | ₹10 Cr | -₹2 Cr | ₹16 L | ₹6 Cr | ₹46 L | ₹2 Cr | ₹8 Cr | ₹8 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹2 Cr | ₹4 Cr | ₹5 Cr | ₹3 Cr | ₹5 Cr | ₹84 L | ₹2 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹88 L | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹2 Cr | ₹1 Cr | ₹73 L | ₹28 L | -₹7 Cr | -₹4 Cr | -₹3 Cr | -₹2 Cr | -₹4 Cr | -₹33 L | -₹70 L | ₹2 L | ₹4 Cr | -₹2 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | -₹2 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹3 Cr | ₹1 Cr | ₹19 L | ₹2 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹18 Cr | ₹20 Cr | ₹19 Cr | ₹18 Cr | ₹21 Cr | ₹15 Cr | ₹12 Cr | ₹12 Cr | ₹9 Cr | ₹6 Cr | ₹12 Cr | ₹12 Cr | ₹10 Cr | ₹13 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | -₹2 Cr | ₹14 L | ₹5 Cr | ₹90 L | ₹1 Cr | ₹7 Cr | ₹5 Cr | ₹7 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹89 L | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹54 L | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹89 L | ₹48 L | -₹7 Cr | -₹4 Cr | -₹3 Cr | -₹1 Cr | -₹3 Cr | -₹63 L | -₹75 L | ₹10 L | ₹2 Cr | -₹2 Cr | ₹67 L | ₹1 Cr | ₹2 Cr | -₹1 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹87 L | ₹14 L | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹9 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr | ₹3 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹441 Cr | ₹368 Cr | ₹303 Cr | ₹270 Cr | ₹226 Cr | ₹190 Cr | ₹169 Cr | ₹167 Cr | ₹148 Cr | ₹132 Cr | ₹122 Cr | ₹118 Cr | ₹116 Cr | ₹108 Cr | ₹105 Cr | ₹121 Cr | ₹126 Cr | ₹126 Cr | ₹124 Cr |
| ₹441 Cr | ₹368 Cr | ₹303 Cr | ₹270 Cr | ₹226 Cr | ₹190 Cr | ₹169 Cr | ₹167 Cr | ₹148 Cr | ₹132 Cr | ₹122 Cr | ₹118 Cr | ₹116 Cr | ₹108 Cr | ₹105 Cr | ₹121 Cr | ₹126 Cr | ₹126 Cr | ₹124 Cr |
| ₹457 Cr | ₹379 Cr | ₹314 Cr | ₹281 Cr | ₹234 Cr | ₹194 Cr | ₹173 Cr | ₹172 Cr | ₹152 Cr | ₹136 Cr | ₹126 Cr | ₹122 Cr | ₹120 Cr | ₹112 Cr | ₹110 Cr | ₹125 Cr | ₹131 Cr | ₹130 Cr | ₹128 Cr |
| ₹2 Cr | ₹3 Cr | ₹9 Cr | ₹10 Cr | ₹12 Cr | ₹13 Cr | ₹5 Cr | ₹12 Cr | ₹19 Cr | ₹18 Cr | ₹16 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 Cr | ₹27 Cr | ₹25 Cr | ₹28 Cr |
| ₹0 | ₹0 | ₹0 | ₹21 L | ₹39 L | ₹89 L | -₹17 L | ₹0 | ₹2 L | ₹2 L | ₹8 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| -₹6 Cr | -₹6 Cr | -₹8 Cr | -₹4 Cr | -₹2 Cr | -₹97 L | -₹51 L | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹59 L | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹27 Cr | ₹8 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹60 L | ₹60 L | ₹60 L | ₹60 L | ₹60 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹9 Cr | ₹7 Cr | ₹8 Cr | ₹9 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹2 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹34 Cr | ₹17 Cr | ₹18 Cr | ₹19 Cr | ₹23 Cr | ₹25 Cr | ₹14 Cr | ₹23 Cr | ₹30 Cr | ₹26 Cr | ₹20 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹4 Cr | ₹30 Cr | ₹27 Cr | ₹30 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹12 Cr | ₹10 Cr | ₹8 Cr | ₹14 Cr | ₹12 Cr | ₹15 Cr | ₹10 Cr | ₹11 Cr | ₹13 Cr | ₹15 Cr | ₹6 Cr | ₹7 Cr | ₹5 Cr | ₹10 Cr | ₹14 Cr | ₹13 Cr | ₹13 Cr | ₹7 Cr | ₹7 Cr |
| ₹48 Cr | ₹51 Cr | ₹37 Cr | ₹38 Cr | ₹31 Cr | ₹26 Cr | ₹27 Cr | ₹25 Cr | ₹22 Cr | ₹25 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹11 Cr | ₹14 Cr | ₹6 Cr | ₹4 Cr | ₹4 Cr |
| ₹0 | ₹0 | ₹5 Cr | ₹0 | ₹0 | ₹8 Cr | ₹18 Cr | ₹5 Cr | ₹13 Cr | ₹19 Cr | ₹10 Cr | ₹4 Cr | ₹7 Cr | ₹12 Cr | ₹19 Cr | ₹18 Cr | ₹0 | ₹0 | ₹0 |
| ₹6 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹8 L | ₹3 Cr | ₹3 Cr | ₹7 Cr | ₹3 Cr | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr |
| ₹66 Cr | ₹64 Cr | ₹54 Cr | ₹57 Cr | ₹47 Cr | ₹53 Cr | ₹57 Cr | ₹43 Cr | ₹50 Cr | ₹59 Cr | ₹29 Cr | ₹21 Cr | ₹27 Cr | ₹31 Cr | ₹45 Cr | ₹48 Cr | ₹21 Cr | ₹13 Cr | ₹14 Cr |
| ₹556 Cr | ₹460 Cr | ₹387 Cr | ₹356 Cr | ₹304 Cr | ₹272 Cr | ₹244 Cr | ₹237 Cr | ₹232 Cr | ₹222 Cr | ₹176 Cr | ₹146 Cr | ₹149 Cr | ₹145 Cr | ₹156 Cr | ₹177 Cr | ₹182 Cr | ₹170 Cr | ₹173 Cr |
| ₹2 Cr | ₹3 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹35 Cr | ₹37 Cr | ₹29 Cr | ₹1 Cr | ₹10 Cr | ₹11 Cr | ₹9 Cr |
| ₹3 Cr | ₹9 Cr | ₹19 Cr | ₹15 Cr | ₹19 Cr | ₹30 Cr | ₹32 Cr | ₹26 Cr | ₹40 Cr | ₹44 Cr | ₹26 Cr | ₹4 Cr | ₹7 Cr | ₹12 Cr | ₹21 Cr | ₹25 Cr | ₹27 Cr | ₹25 Cr | ₹28 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹544 Cr | ₹427 Cr | ₹331 Cr | ₹300 Cr | ₹266 Cr | ₹216 Cr | ₹197 Cr | ₹180 Cr | ₹166 Cr | ₹98 Cr | ₹231 Cr | ₹222 Cr | ₹212 Cr | ₹206 Cr | ₹207 Cr | ₹202 Cr | ₹175 Cr | ₹157 Cr | ₹149 Cr |
| ₹239 Cr | ₹197 Cr | ₹166 Cr | ₹133 Cr | ₹105 Cr | ₹88 Cr | ₹66 Cr | ₹45 Cr | ₹25 Cr | ₹10 Cr | ₹143 Cr | ₹134 Cr | ₹122 Cr | ₹113 Cr | ₹101 Cr | ₹85 Cr | ₹69 Cr | ₹55 Cr | ₹41 Cr |
| ₹305 Cr | ₹230 Cr | ₹166 Cr | ₹168 Cr | ₹162 Cr | ₹128 Cr | ₹131 Cr | ₹135 Cr | ₹140 Cr | ₹88 Cr | ₹88 Cr | ₹88 Cr | ₹90 Cr | ₹93 Cr | ₹105 Cr | ₹116 Cr | ₹106 Cr | ₹101 Cr | ₹108 Cr |
| ₹18 Cr | ₹38 Cr | ₹59 Cr | ₹12 Cr | ₹31 L | ₹17 Cr | ₹2 Cr | ₹4 Cr | ₹0 | ₹53 Cr | ₹6 Cr | ₹0 | ₹2 Cr | ₹30 L | ₹0 | ₹1 Cr | ₹26 Cr | ₹23 Cr | ₹13 Cr |
| ₹0 | ₹0 | ₹0 | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹7 Cr | ₹11 Cr | ₹10 Cr | ₹9 Cr | ₹6 Cr | ₹8 Cr | ₹11 Cr | ₹12 Cr | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹10 Cr | ₹8 Cr | ₹0 | ₹0 | ₹0 |
| ₹5 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹331 Cr | ₹273 Cr | ₹229 Cr | ₹193 Cr | ₹180 Cr | ₹162 Cr | ₹148 Cr | ₹145 Cr | ₹149 Cr | ₹152 Cr | ₹105 Cr | ₹90 Cr | ₹96 Cr | ₹97 Cr | ₹115 Cr | ₹125 Cr | ₹131 Cr | ₹124 Cr | ₹121 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹30 Cr | ₹25 Cr | ₹25 Cr | ₹23 Cr | ₹17 Cr | ₹15 Cr | ₹17 Cr | ₹19 Cr | ₹18 Cr | ₹15 Cr | ₹16 Cr | ₹16 Cr | ₹11 Cr | ₹11 Cr | ₹13 Cr | ₹20 Cr | ₹16 Cr | ₹13 Cr | ₹10 Cr |
| ₹106 Cr | ₹106 Cr | ₹87 Cr | ₹80 Cr | ₹77 Cr | ₹73 Cr | ₹58 Cr | ₹59 Cr | ₹56 Cr | ₹42 Cr | ₹38 Cr | ₹26 Cr | ₹28 Cr | ₹26 Cr | ₹26 Cr | ₹29 Cr | ₹23 Cr | ₹22 Cr | ₹31 Cr |
| ₹65 Cr | ₹33 Cr | ₹26 Cr | ₹39 Cr | ₹11 Cr | ₹7 Cr | ₹7 Cr | ₹3 Cr | ₹3 Cr | ₹1 Cr | ₹3 Cr | ₹1 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹3 Cr |
| ₹15 Cr | ₹16 Cr | ₹13 Cr | ₹14 Cr | ₹12 Cr | ₹11 Cr | ₹9 Cr | ₹7 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹65 L | ₹54 L | ₹63 L | ₹61 L | ₹63 L | ₹67 L | ₹4 L |
| ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹8 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹9 Cr | ₹11 Cr | ₹12 Cr | ₹10 Cr | ₹8 Cr | ₹80 L | ₹1 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr |
| ₹225 Cr | ₹188 Cr | ₹158 Cr | ₹163 Cr | ₹125 Cr | ₹110 Cr | ₹96 Cr | ₹92 Cr | ₹84 Cr | ₹70 Cr | ₹70 Cr | ₹57 Cr | ₹53 Cr | ₹48 Cr | ₹41 Cr | ₹52 Cr | ₹50 Cr | ₹45 Cr | ₹50 Cr |
| ₹159 Cr | ₹123 Cr | ₹104 Cr | ₹106 Cr | ₹77 Cr | ₹58 Cr | ₹39 Cr | ₹49 Cr | ₹34 Cr | ₹10 Cr | ₹41 Cr | ₹36 Cr | ₹27 Cr | ₹16 Cr | -₹3 Cr | ₹4 Cr | ₹29 Cr | ₹33 Cr | ₹36 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹40 L | ₹80 L | ₹1 Cr |
| ₹556 Cr | ₹460 Cr | ₹387 Cr | ₹356 Cr | ₹304 Cr | ₹272 Cr | ₹244 Cr | ₹237 Cr | ₹232 Cr | ₹222 Cr | ₹176 Cr | ₹146 Cr | ₹149 Cr | ₹145 Cr | ₹156 Cr | ₹177 Cr | ₹182 Cr | ₹170 Cr | ₹173 Cr |
| ₹101 | ₹167 | ₹139 | ₹124 | ₹104 | ₹88 | ₹78 | ₹78 | ₹69 | ₹62 | ₹57 | ₹55 | ₹54 | ₹51 | ₹50 | ₹57 | ₹59 | ₹58 | ₹57 |
| ₹101 | ₹84 | ₹69 | ₹62 | ₹52 | ₹44 | ₹78 | ₹78 | ₹69 | ₹62 | ₹57 | ₹55 | ₹54 | ₹51 | ₹50 | ₹57 | ₹59 | ₹58 | ₹57 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹104 Cr | ₹90 Cr | ₹54 Cr | ₹64 Cr | ₹55 Cr | ₹28 Cr | ₹8 Cr | ₹35 Cr | ₹26 Cr | ₹17 Cr | ₹8 Cr | ₹7 Cr | ₹18 Cr | ₹4 Cr | -₹16 Cr | -₹4 Cr | ₹4 Cr | ₹6 Cr | ₹10 Cr |
| ₹51 Cr | ₹34 Cr | ₹37 Cr | ₹39 Cr | ₹31 Cr | ₹29 Cr | ₹23 Cr | ₹30 Cr | ₹23 Cr | ₹12 Cr | ₹11 Cr | ₹12 Cr | ₹11 Cr | ₹17 Cr | ₹21 Cr | ₹19 Cr | ₹17 Cr | ₹18 Cr | ₹18 Cr |
| ₹16 Cr | -₹8 Cr | -₹15 Cr | -₹4 Cr | -₹11 Cr | -₹13 Cr | -₹85 L | -₹16 Cr | -₹9 Cr | ₹63 L | -₹19 Cr | -₹1 Cr | -₹8 Cr | -₹5 Cr | ₹8 Cr | -₹5 Cr | ₹5 Cr | ₹3 Cr | -₹11 Cr |
| ₹171 Cr | ₹116 Cr | ₹76 Cr | ₹99 Cr | ₹75 Cr | ₹44 Cr | ₹30 Cr | ₹49 Cr | ₹39 Cr | ₹29 Cr | ₹63 L | ₹17 Cr | ₹21 Cr | ₹16 Cr | ₹13 Cr | ₹9 Cr | ₹26 Cr | ₹26 Cr | ₹17 Cr |
| ₹147 Cr | ₹94 Cr | ₹61 Cr | ₹87 Cr | ₹59 Cr | ₹37 Cr | ₹24 Cr | ₹39 Cr | ₹33 Cr | ₹24 Cr | -₹1 Cr | ₹15 Cr | ₹17 Cr | ₹16 Cr | ₹13 Cr | ₹8 Cr | ₹24 Cr | ₹24 Cr | ₹13 Cr |
| -₹130 Cr | -₹76 Cr | -₹76 Cr | -₹57 Cr | -₹38 Cr | -₹32 Cr | -₹20 Cr | -₹16 Cr | -₹24 Cr | -₹39 Cr | -₹16 Cr | -₹8 Cr | -₹8 Cr | -₹4 Cr | -₹4 Cr | -₹3 Cr | -₹22 Cr | -₹18 Cr | -₹21 Cr |
| -₹10 Cr | -₹16 Cr | -₹2 Cr | -₹11 Cr | -₹16 Cr | -₹5 Cr | -₹1 Cr | -₹23 Cr | -₹8 Cr | ₹13 Cr | ₹19 Cr | -₹9 Cr | -₹8 Cr | -₹11 Cr | -₹9 Cr | -₹6 Cr | -₹2 Cr | -₹8 Cr | -₹12 Cr |
| ₹7 Cr | ₹2 Cr | -₹17 Cr | ₹19 Cr | ₹5 Cr | ₹53 L | ₹3 Cr | ₹67 L | ₹1 Cr | -₹2 Cr | ₹2 Cr | -₹96 L | ₹4 L | ₹63 L | -₹19 L | -₹97 L | ₹1 Cr | -₹1 Cr | -₹20 Cr |
| ₹16 Cr | ₹13 Cr | ₹31 Cr | ₹11 Cr | ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹63 L | ₹3 Cr | ₹48 L | ₹1 Cr | ₹1 Cr | ₹77 L | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹3 Cr | ₹23 Cr |
| ₹1 L | -₹10,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹23 Cr | ₹16 Cr | ₹13 Cr | ₹30 Cr | ₹11 Cr | ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹63 L | ₹3 Cr | ₹48 L | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹3 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Vimta Labs Share Price
467.65+0.00 (-0.91%)
-23.52% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 1
Bearish signals: 6 out of 9 oscillators
RSI
33.70Sell
STOCH %K
20.08Neutral
MACD Level(12,26)
-16.25Sell
Ultimate Oscillator
39.81Sell
Aroon Oscillator
-98.00Sell
BOP
-0.59Sell
CCI
-161.58Buy
Williams %R
-79.92Neutral
Momentum
-15.95Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 9 out of 9 moving averages
EMA 9
484.39Sell
SMA 9
490.09Sell
EMA 21
498.21Sell
SMA 21
493.94Sell
EMA 50
528.17Sell
SMA 50
540.44Sell
EMA 200
548.15Sell
SMA 200
522.59Sell
WMA 20
491.30Sell
Pivot
Pivot
Classic
Resistance 5
540.60
Resistance 4
522.15
Resistance 3
503.70
Resistance 2
485.25
Resistance 1
478.60
Pivot
466.80
Support 1
460.15
Support 2
448.35
Support 3
429.90
Support 4
411.45
Support 5
393.00
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Vimta Labs Share Price
467.65+0.00 (-0.91%)
-23.52% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 35.64% | 35.67% | 35.85% | 35.90% | 35.99% | 36.67% |
| 5.07% | 4.41% | 4.89% | 4.59% | 4.33% | 3.49% |
| 0.25% | 0.17% | 0.13% | 0.11% | 0.87% | 1.42% |
| 0.23% | 0.20% | 0.00% | 0.00% | 0.00% | 0.00% |
| 58.81% | 59.55% | 59.13% | 59.40% | 58.81% | 58.42% |
Bulk & block deals
Name
Microcurves Trading Private Limited
Microcurves Trading Private Limited
Hrti Private Limited
Hrti Private Limited
Graviton Research Capital Llp
Graviton Research Capital Llp
Hrti Private Limited
Spdr Portfolio Emerging Markets Etf
Hrti Private Limited
Hrti Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 21 Jul 2026 | Sell | 22.14 Cr | ₹604.27 | 3.66 L | Bulk | 0.819808 | NSE |
| 21 Jul 2026 | Purchase | 22.12 Cr | ₹603.90 | 3.66 L | Bulk | 0.819808 | NSE |
| 25 Sep 2025 | Sell | 22.24 Cr | ₹755.68 | 2.94 L | Bulk | 0.659412 | NSE |
| 25 Sep 2025 | Purchase | 22.23 Cr | ₹753.57 | 2.95 L | Bulk | 0.661046 | NSE |
| 19 Sep 2025 | Sell | 20.43 Cr | ₹821.90 | 2.49 L | Bulk | 0.557029 | NSE |
| 19 Sep 2025 | Purchase | 20.42 Cr | ₹821.32 | 2.49 L | Bulk | 0.557029 | NSE |
| 19 Sep 2025 | Sell | 32.39 Cr | ₹822.81 | 3.94 L | Bulk | 0.88186 | NSE |
| 19 Sep 2025 | Purchase | 28.54 Cr | ₹824.05 | 3.46 L | Bulk | 0.776009 | NSE |
| 19 Sep 2025 | Purchase | 30.94 Cr | ₹821.31 | 3.77 L | Bulk | 0.844054 | NSE |
| 11 Sep 2025 | Sell | 20.36 Cr | ₹806.18 | 2.53 L | Bulk | 0.565822 | NSE |
Insider trading & SAST
Client name
Jagadeesh Kodali
Jagadeesh Kodali
Harriman Vungal
Harriman Vungal & Others
Harriman Vungal
Sudheshna Vungal
Sireesh Chandra Vungal
Vungal Rajeswari
Vasireddi Veerabhadra Prasad & Others
Sujani Vasireddi
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 Mar 2026 | Designated Person | Disposal | 0.011202 | 0.02 | 23.20 L | ₹464 | 5 K | 25 Feb 2026 | Gift | 10,028 | Insider Trading | — | Equity Shares |
| 10 Mar 2026 | Designated Person | Disposal | 0.011193 | 0.02 | 23.20 L | ₹464 | 5 K | 25 Feb 2026 | Gift | 10,028 | Insider Trading | — | Equity Shares |
| 11 Aug 2025 | Promoter & Director | Disposal | 0.022469 | 6.93 | 64.92 L | ₹649.25 | 10 K | 07 Aug 2025 | Gift | 30,85,636 | Insider Trading | — | Equity Shares |
| 15 Jul 2025 | Promoter | Acquisition | 1.02 | 9.29 | 0 | — | 4.50 L | 27 Jun 2025 | Off Market | 41,34,954 | SAST | 29(2) | — |
| 02 Jul 2025 | Promoter & Director | Disposal | 1.011109 | 6.96 | 19.72 Cr | ₹438.20 | 4.50 L | 27 Jun 2025 | Gift | 30,95,636 | Insider Trading | — | Equity Shares |
| 02 Jul 2025 | Promoter Group | Acquisition | 0.224691 | 0.68 | 4.38 Cr | ₹438.20 | 1 L | 27 Jun 2025 | Gift | 3,01,758 | Insider Trading | — | Equity Shares |
| 02 Jul 2025 | Promoter Group | Acquisition | 0.224691 | 0.73 | 4.38 Cr | ₹438.20 | 1 L | 27 Jun 2025 | Gift | 3,26,110 | Insider Trading | — | Equity Shares |
| 02 Jul 2025 | Promoter Group | Acquisition | 0.561727 | 0.92 | 10.96 Cr | ₹438.20 | 2.50 L | 27 Jun 2025 | Gift | 4,11,450 | Insider Trading | — | Equity Shares |
| 16 Jun 2025 | Promoter | Acquisition | 4.27 | 6.89 | 0 | — | 9.50 L | 28 May 2025 | Off Market | 15,32,140 | SAST | 29(2) | — |
| 02 Jun 2025 | Promoter Group | Acquisition | 1.572836 | 1.87 | 34.17 Cr | ₹976.40 | 3.50 L | 28 May 2025 | Gift | 4,16,325 | Insider Trading | — | Equity Shares |
Vimta Labs Share Price
467.65+0.00 (-0.91%)
-23.52% past 1 Year
Vimta Labs Limited was established in 1984 and is a company driven by its vision and enduring strength. The company's business landscape includes analytical clinical preclinical services to life sciences
Corporate Actions
Date
Type
Details
Company details
Vimta Labs Share Price
467.65+0.00 (-0.91%)
-23.52% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Vimta Labs Share Price
467.65+0.00 (-0.91%)
-23.52% past 1 Year
News
1 of 20
ResultVIMTALABS30 Oct 2026
Vimta Labs reported second quarter EBITDA of Rs 37.80 crores, compared with Rs 34.20 crores in the corresponding year ago quarter, representing year on year growth of approximately 10.5%. EBITDA margin improved marginally to 33.82% from 33.61% year on year, indicating stable operating profitability. Revenue and PAT figures, along with quarter on quarter comparisons, were not provided in the available update. The reported EBITDA growth and slight margin expansion reflect an improvement in operating performance, while the absence of broader financial figures limits assessment of overall quarterly earnings.
Vimta Labs Reports Q2 Revenue Growth To Rs 110 Crores From Rs 100 Crores
ResultVIMTALABS30 Oct 2026
Vimta Labs reported Q2 revenue of Rs 110 crores, compared with Rs 100 crores in the corresponding quarter a year earlier, representing 10 percent YoY growth. EBITDA, PAT, operating margin, net margin, QoQ performance, and analyst consensus estimates were not provided. The revenue increase indicates higher quarterly operating income, while the available information does not support further conclusions on profitability or margin movement.
Vimta Labs Reports Marginal Year On Year Growth In Second Quarter Net Profit
ResultVIMTALABS30 Oct 2026
Vimta Labs reported second quarter standalone net profit of Rs 20.60 crores, compared with Rs 19.90 crores in the corresponding quarter of the previous year, representing growth of approximately 3.5 percent year on year. Revenue, EBITDA, operating margin, net margin, sequential performance and analyst expectations were not provided in the available update. The result indicates modest improvement in quarterly profitability, with no additional management guidance or market reaction reported.
Vimta Labs sees strong pharma demand, new biologics facility to lift margins
Stock NewsVIMTALABS21 Jul 2026
Vimta Labs Ltd, a leading contract research and testing organization, has highlighted a positive demand outlook across its core segments, particularly pharmaceutical research and a recovering clinical research franchise. Management commentary indicates that current inquiry trends and strong demand pipelines are expected to support performance in coming quarters, with pharma remaining the key growth driver and clinical research activity gradually normalizing. This is consistent with the company’s recent double-digit revenue and profit growth, where pharma and food testing have accounted for the bulk of revenues, supported by capacity additions and process automation across facilities.
A key strategic development is the new biologics contract research and development facility, which has recently secured its first domestic order following commercial launch. The facility, operationalized in Q1 of the current financial cycle, marks an important diversification into high-growth biologics services. Management expects this biologics platform to significantly enhance overall revenue and margin profile starting from the third year of operations, as utilization ramps up and more domestic and international mandates are onboarded. The company has been investing consistently in capacity expansion and specialized infrastructure, including biologics and advanced life sciences capabilities, while maintaining a net debt-free balance sheet and healthy cash reserves, which supports its growth plans without adding financial leverage.
From an earnings impact perspective, sustained traction in pharma outsourcing, incremental recovery in clinical research, and the scale-up of biologics services together point to a structurally improving revenue mix with potential margin accretion over the medium term. While no specific guidance has been provided on quarterly earnings or exact margin levels from biologics, the combination of strong order visibility, first biologics mandate, and prior track record of maintaining robust EBITDA and PAT margins indicates that the company is positioned to strengthen its market share in India’s CRO and testing space over the next few years. Near-term share price impact will depend on how quickly biologics revenues ramp up and whether inquiry conversion in pharma and clinical research sustains at current levels.
Vimta Labs sees stable margins ahead despite Q1 operating pressure and costs
Stock NewsVIMTALABS21 Jul 2026
Vimta Labs, a diversified testing and contract research services company, has indicated that it does not expect any further drop in operating margins going forward, even though its Q1 operating margins declined quarter-on-quarter. The margin compression in the latest reported quarter was attributed to higher facility costs, implementation of new labor laws, and rupee appreciation, which together increased the company’s cost base. Management commentary suggests that these factors are largely front-loaded and that the business is now positioned to absorb the incremental costs without additional margin erosion, supported by anticipated growth in core service lines.
The company’s revenue profile is driven primarily by pharmaceutical testing and contract research services, supplemented by food testing and other specialized testing activities, and recent quarters have shown healthy topline and profit growth as demand improved in pharma-related businesses. This operational backdrop underpins Vimta Labs’ confidence that business growth can offset the impact of higher structural costs, allowing margins to stabilise from current levels. While Q1 operating margins were lower versus the previous quarter, earnings metrics such as EBITDA and profit after tax have continued to expand year-on-year in recent disclosures, indicating resilient underlying demand and capacity utilisation trends.
From an earnings perspective, any stabilisation or gradual recovery in operating margins, combined with ongoing volume growth in key testing segments, would be supportive of future profitability. The company’s outlook that margins will not deteriorate further suggests that recent cost pressures are being managed and that pricing, mix, and efficiency measures may help protect operating performance. No specific corporate actions such as buyback, dividend changes, rights issue, or major leverage-altering transactions are highlighted in the context provided, and there is no explicit mention of immediate market-wide impact or index-level implications from this update.
Vimta Labs targets 20–25 percent revenue growth for FY27 despite flat Q1 run rate
Stock NewsVIMTALABS21 Jul 2026
Vimta Labs, a leading Indian contract research and testing organization listed on NSE and BSE, has guided for robust top line expansion in the current financial year. Management has indicated a target of around 20 percent to 25 percent revenue growth for FY27, reflecting confidence in the underlying demand environment and the scaling up of its diversified testing and research portfolio. This growth ambition comes on the back of steady execution and capacity additions, including its recently operational biologics contract research and development facility, which is expected to contribute meaningfully as inquiries ramp up from both domestic and international clients.
For Q1 FY27, Vimta Labs reported total income of approximately Rs 112.90 crores, translating into 13.7 percent year on year growth. The quarterly revenue was largely stable versus Q4 FY26 levels, indicating a relatively flat sequential run rate even as year on year trends remained firmly positive. Management commentary in the latest investor interactions suggests that the company is aiming for an annual revenue profile closer to Rs 500 crores for FY27, consistent with the 20 percent to 25 percent growth band, assuming normalization of clinical research activity and continued traction in pharmaceutical and food testing segments. The focus remains on improving utilization of existing infrastructure, deepening relationships with key clients, and capturing incremental market share in higher value added research services.
From an earnings and leverage perspective, the targeted revenue expansion, if achieved with disciplined cost control, is likely to support operating margin resilience and healthy cash generation. This, in turn, can enhance the company’s ability to fund future capex and technology upgrades without materially stressing the balance sheet. While Q1 FY27 does not show a sharp quarter on quarter acceleration, the double digit year on year growth, combined with a clear medium term guidance band, positions Vimta Labs as a growth oriented mid cap player within India’s healthcare and research services space. No material corporate actions such as buybacks, large M&A, or rights issues are indicated in the provided context, so the near term narrative is primarily centered on organic growth, capacity scaling, and demand recovery in clinical research.
Vimta Labs posts higher Q1 revenue, EBITDA and PAT on year
ResultVIMTALABS20 Jul 2026
Vimta Labs reported Q1 revenue of Rs 110.00 crores versus Rs 97.60 crores a year earlier, indicating a 12.7 percent YoY increase based on the figures provided.
The context does not provide EBITDA, PAT, or margin data for this specific update, so those metrics are not included. The result headline indicates routine quarterly earnings performance for the company, with no additional details on guidance, commentary, or market reaction.
Vimta Labs Q1 EBITDA grows year-on-year amid marginal margin compression
ResultVIMTALABS20 Jul 2026
Vimta Labs reported a healthy year-on-year improvement in operating performance for the latest reported quarter, with Q1 EBITDA rising to about Rs 37.30 crores from Rs 33.70 crores in the corresponding period last year. This represents a solid increase in absolute operating earnings on a yearly basis, indicating improved scale and operating leverage in the core business. The reported Q1 EBITDA margin stood at 34.21%, slightly lower than 34.53% in the same quarter last year, suggesting a marginal compression in operating profitability despite the growth in absolute EBITDA. This mild dip in margin indicates that while the company has grown its operating profit pool, cost pressures or mix effects have limited further margin expansion on a year-on-year basis.
Within this context, the key takeaway for market participants is the combination of robust year-on-year EBITDA growth with only a modest decline in EBITDA margin. The expansion in EBITDA in rupee terms underscores resilient demand for the company’s services and an ability to convert revenue growth into higher operating profits. At the same time, the slight margin contraction will likely keep investor focus on cost management, pricing discipline, and business mix in subsequent quarters. No additional data on revenue, PAT, or quarter-on-quarter trends is provided in the current context, and there is no reference to street expectations, guidance, or immediate stock price reaction. As a result, the analysis remains centred on the operating performance metrics disclosed, highlighting that operational momentum remains positive in absolute terms, even as margin trends warrant monitoring in future results.
Vimta Labs Q1 standalone net profit rises year-on-year to Rs 21 crores
ResultVIMTALABS20 Jul 2026
Vimta Labs reported a strong year-on-year improvement in profitability for the latest reported first quarter, with standalone net profit rising to about Rs 21 crores compared with roughly Rs 18.90 crores in the corresponding period last year. This reflects a healthy double-digit growth in profit after tax, indicating robust operational performance and improved earnings momentum. While detailed revenue, EBITDA and margin data for this specific quarter are not provided in the given context, the consistent uptick in net profit suggests that the company is benefiting from stable demand for its contract research and testing services and effective cost management.
Recent filings and reputable Indian media coverage around the March 2026 quarter showed Vimta Labs delivering year-on-year growth in both sales and profitability, supported by an expanding base of pharmaceutical and food contract research and testing services. Though exact revenue and margin metrics for the current Q1 release are not specified here, the continued increase in net profit aligns with the broader trend of Vimta Labs scaling its operations and enhancing earnings. In the absence of explicit street expectations, consensus numbers or intraday stock price reaction for this particular result, the earnings update appears to be a routine, albeit positive, progression rather than a market-moving surprise for the wider indices.
Overall, the Q1 standalone net profit performance reinforces Vimta Labs’ trajectory of steady earnings growth, supported by its positioning as a leading contract research and testing organization in India. The improvement in profit after tax on a year-on-year basis, without any indication of a sharp deviation from prior trends or macro-sensitive triggers, suggests that the announcement is likely to have a limited but constructive impact on the stock, primarily relevant for company-specific investors tracking its earnings cycle.
Vimta Labs schedules Q1 FY27 earnings conference call for July 20, 4 pm
Stock NewsVIMTALABS15 Jul 2026
Vimta Labs has announced that it will hold its Q1 earnings conference call on July 20 at 4 pm. The scheduled interaction indicates that the company is prepared to discuss its financial and operational performance for the first quarter of the current financial year with analysts and investors. Such earnings calls typically cover revenue trends, profitability, segment performance, and key business developments, along with management commentary on demand outlook, capacity utilisation, and strategic initiatives.
While the specific financial metrics for the quarter are not disclosed in the available context, the announcement of an earnings call itself is a routine but important part of corporate communication, helping the market to assess the company’s near-term trajectory once detailed numbers and guidance are shared. Participants in the call generally seek clarity on growth drivers, margin sustainability, order pipeline, regulatory environment, and any notable changes in the company’s operating landscape.
In the absence of published Q1 results, there is no verifiable information yet on how the quarter’s performance may impact earnings, leverage, or market share for Vimta Labs. The market’s eventual reaction will depend on whether reported numbers and management commentary are ahead of, in line with, or below prevailing expectations. For now, the scheduled Q1 earnings call is best viewed as a standard event that will provide an opportunity for stakeholders to obtain detailed, updated insights into the company’s business performance and outlook once the call takes place.
Vimta Labs - Quaterly Results
ResultVIMTALABS6 May 2026
NULL
Vimta Labs reports Profit after tax of 21.11 Crores, in the March 2026 quarter
ResultVIMTALABS6 May 2026
NULL
Vimta Labs Recommends Dividend of Rs 2 Per Share.
ResultVIMTALABS6 May 2026
Vimta Labs has recommended a dividend of Rs 2 per share. This corporate action follows the company's board meeting where the dividend declaration was approved, signaling confidence in its financial position and commitment to shareholder returns. Vimta Labs, listed under the symbol VIMTALABS on NSE/BSE, operates in the testing and analytical services sector, providing services across pharmaceuticals, food, and environmental testing.
The announcement pertains to the latest earnings or corporate results period, though specific details on revenue, EBITDA, PAT, or year-over-year changes are not provided in the available context. Dividend recommendations typically reflect sustained profitability and cash flow generation. No information on margin trends, comparisons to street expectations, or management guidance is included. Market reaction to the news is not specified.
Vimta Labs Q4 EBITDA Growth Outpaces YoY with Margin Expansion
ResultVIMTALABS6 May 2026
Vimta Labs reported Q4 EBITDA of Rs 39.30 crores, representing a YoY increase from Rs 33.00 crores in the corresponding quarter of the previous fiscal year. This reflects a YoY growth of approximately 19.1%. The company demonstrated margin improvement with Q4 EBITDA margin expanding to 36.04% from 34.98% YoY, indicating a 106 basis point enhancement in operational efficiency. The margin expansion suggests improved cost management and operational leverage during the quarter. The earnings trajectory reflects positive operational momentum with both absolute EBITDA growth and margin accretion, signaling strengthened profitability metrics.
Vimta Labs Reports Q4 Net Profit of Rs 21.10 Crores, Up YoY from Rs 18.32 Crores
ResultVIMTALABS6 May 2026
Vimta Labs announced its Q4 financial results, recording a net profit of Rs 21.10 crores, marking an improvement from Rs 18.32 crores in the same quarter of the previous year. Revenue for the quarter stood at Rs 110.00 crores, reflecting growth from Rs 94.44 crores YoY.
The year-over-year increase in both top-line and bottom-line figures indicates stronger operational performance in the quarter. No details on EBITDA, margins, or comparisons to street expectations were provided in the announcement. QoQ figures were not mentioned.
Vimta Labs informs about analyst meet
Stock NewsVIMTALABS23 Feb 2026
NULL
Vimta Labs - Quaterly Results
ResultVIMTALABS28 Jan 2026
NULL
Vimta Labs reports Profit after tax of 17.59 Crores, in the December 2025 quarter
ResultVIMTALABS28 Jan 2026
NULL
Vimta Labs Q3FY25 Net Profit Rises 112.2% YoY to Rs 21.50 Crores.
ResultVIMTALABS28 Jan 2026
Vimta Labs Ltd reported Q3FY25 results with total income of Rs 91.15 crores, up 6.7% QoQ from Rs 85.43 crores and 10.4% YoY from Rs 82.57 crores. Profit after tax (PAT) stood at Rs 21.50 crores, reflecting a 41.0% QoQ increase from Rs 15.25 crores and a 112.2% YoY growth from Rs 10.13 crores. Earnings per share (EPS) was Rs 9.60, up 41.2% QoQ and 113.3% YoY from Rs 4.50.
Profit before tax (PBT) reached Rs 23.92 crores, marking a 9.3% QoQ rise from Rs 21.89 crores and 77.2% YoY surge from Rs 13.50 crores. Total expenses were Rs 67.23 crores, increasing 5.8% QoQ from Rs 63.54 crores but down 2.7% YoY from Rs 69.07 crores. Tax expense was Rs 6.40 crores, up 31.1% QoQ and 89.9% YoY. These figures indicate strong profitability growth despite moderate revenue expansion and controlled expenses YoY.
Vimta Labs Q3 EBITDA at Rs 34.20 Crores, Up Slightly YoY; Margin Contracts to 34.7%.
ResultVIMTALABS28 Jan 2026
Vimta Labs reported Q3 EBITDA of Rs 34.20 crores, marking a marginal increase from Rs 33.10 crores YoY. EBITDA margin stood at 34.7%, down from 36.82% YoY.
Additional financial details from company results include total income of Rs 91.15 crores, up 6.7% QoQ from Rs 85.43 crores and 10.4% YoY from Rs 82.57 crores. Total expenses were Rs 67.23 crores, rising 5.8% QoQ but down 2.7% YoY from Rs 69.07 crores. Profit before tax grew to Rs 23.92 crores, up 9.3% QoQ and 77.2% YoY. Profit after tax surged to Rs 21.50 crores, reflecting 41.0% QoQ growth from Rs 15.25 crores and 112.2% YoY from Rs 10.13 crores. Earnings per share reached Rs 9.60, up 41.2% QoQ and 113.3% YoY from Rs 4.50.[1]
Additional financial details from company results include total income of Rs 91.15 crores, up 6.7% QoQ from Rs 85.43 crores and 10.4% YoY from Rs 82.57 crores. Total expenses were Rs 67.23 crores, rising 5.8% QoQ but down 2.7% YoY from Rs 69.07 crores. Profit before tax grew to Rs 23.92 crores, up 9.3% QoQ and 77.2% YoY. Profit after tax surged to Rs 21.50 crores, reflecting 41.0% QoQ growth from Rs 15.25 crores and 112.2% YoY from Rs 10.13 crores. Earnings per share reached Rs 9.60, up 41.2% QoQ and 113.3% YoY from Rs 4.50.[1]

